Wolverine Stack: BPC-157 combined with TB-500 at doses individualized to injury severity
Conclusion: Fifty years after its initial discovery, GHK-Cu continues to generate compelling research interest for a straightforward reason: no other single peptide compound has demonstrated comparable breadth of biological activity at such low concentrations
It is not approved by the MHRA as a medicine for human therapeutic use and is supplied for investigational purposes in line with UK regulatory frameworks
Ongoing low-dose maintenance (experimental) Continuous dosing approach: Dose: 1-2mg daily OR 3-5mg 2-3x weekly Duration: Ongoing (not cycled) Goal: Maintain constant telomerase activation Status: Experimental, not from research protocols Rationale: Telomerase needs continuous activation to maintain telomere length Cyclic dosing may allow regression between cycles Low-dose continuous might provide stable benefits Similar to maintenance protocols for other peptides Continuous dosing options: Advantages of continuous: No "off" periods where benefits regress Potentially stronger cumulative anti-aging More like natural physiologic regulation Easier to stack with other peptides Disadvantages: Much higher annual cost ($1,800-3,600 vs $300-600) No long-term safety data Uncertain if better than cyclic approach Storage challenges (more reconstitution) Deviates from proven protocols Current recommendation: Stick with proven 10-day cycles for most users Consider continuous only if cyclic approach inadequate Start with standard protocol first Assess your individual response Consult with peptide-knowledgeable physician Use our peptide cycle planning guide to design your Epithalon protocol
Research highlights its role in extending cellular lifespan, enhancing immune function, regulating melatonin secretion, and protecting genomic stability
